Sign in
Taking people in United StatesPhase 3

Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment

Key facts

Who runs it
Rutgers, The State University of New Jersey
Where
New Brunswick and Salt Lake City, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
450 people, planned
Started
4 Sept 2023
Expected to end
31 Jul 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • MORE
  • SMP
  • TAU
Record updated
30 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • English-speaking
  • age ≥18
  • currently on methadone
  • persistent or recurring pain that has lasted for a duration of 3 months of longer

Who cannot take part

  • previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33 studies)
  • severe cognitive impairment (score >23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)
  • suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)
  • inability to attend or fully participate in intervention sessions or assessments

This trial is currently available in United States.

  • Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United StatesContact: Nina CoopermanTaking people
  • University of UtahSalt Lake City, United StatesContact: Ericc Garland, PhDTaking people

About the trial

What the trial wants to find out

This hybrid implementation-effectiveness trial will evaluate Mindfulness-Oriented Recovery Enhancement (MORE) for patients with opioid use disorder receiving methadone treatment (MT). The investigators will also assess barriers and facilitators to integrating MORE into methadone treatment, and evaluate the impact of a sustainable train-the-trainer model on provider burden, intervention fidelity, intervention engagement, and outcomes. Participants will be assigned to a higher intensity MORE implementation strategy, a minimal intensity implementation strategy consisting of a simple, scripted mindfulness practice (SMP) extracted from the MORE treatment manual with minimal training and feedback and no supervision, or methadone treatment as usual (TAU). We aim to:

Read full original descriptionShow less

* Examine barriers and facilitators to the implementation of MORE and SMP in MT and evaluate strategies for optimizing training, fidelity, and engagement. * Evaluate the effectiveness and treatment fidelity of a higher intensity MORE implementation strategy versus a lower intensity, scripted mindfulness practice (SMP) implementation strategy as an adjunct to methadone TAU or methadone TAU, only. Outcomes include opioid and other drug use, craving, MT discontinuation, depression, anxiety, and physical pain (secondary outcomes) than patients randomized to TAU.

The 3 groups in the trial

  • MORETreatment being tested

    Eight group sessions of Mindfulness-Oriented Recovery Enhancement plus methadone treatment as usual (TAU)

  • Scripted Mindfulness Practice (SMP)Existing treatment, for comparison

    Eight group sessions of scripted mindfulness practice plus TAU.

    Treatment: SMP

  • Treatment-as-UsualExisting treatment, for comparison

    Methadone treatment as usual.

    Treatment: TAU

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use Disorder and Chronic Pain
Publications
Record updated
30 July 2025